janagliflozin + metformin

Janagliflozin + metformin is a fixed-dose combination of two oral antidiabetic agents intended for the treatment of type 2 diabetes mellitus. Janagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor, which lowers blood glucose by promoting urinary glucose excretion. Metformin is a biguanide that decreases hepatic glucose production, reduces intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. The combination targets hyperglycemia through complementary mechanisms—janagliflozin acts primarily in the kidneys while metformin acts mainly in the liver and peripheral tissues. This dual approach helps improve glycemic control in adults with type 2 diabetes when diet and exercise alone are insufficient.